Clinical Practice Change





New Vitamin D (25(OH)D) Ordering Criteria and Requisition

Date Effective: February 1, 2016

Date Issued: January 21, 2016

Clinical Practice Change for Ordering Practitioners:

- 25-hydroxy vitamin D (25(OH)D) testing will only be performed for patients meeting the new medically indicated criteria, as outlined on the new requisition form. *Please see new requisition attached as Appendix A, which identifies medically indicated criteria.*
- The new requisition form, available in your Electronic Medical Record (QHR, Jonoke and Med-Access) and on the Diagnostic Services Manitoba (DSM) Laboratory Information Manual (https://apps.sbgh.mb.ca/labmanual/document/listRequisitions?labId=1), must be used for 25(OH)D; if the requisition is not available in your EMR, please contact your vendor for assistance; DSM is making every effort to remove or amend all requisitions with a 25(OH)D ordering cue; while some requisitions may still be available, they will not be honoured after May 2, 2016.
- The new 25(OH)D requisition requires the signature of the ordering practitioner and will not be processed when the signature is missing.

Rationale for Change:

• Clinical evidence shows that screening for vitamin D deficiency in healthy individuals is generally not necessary as it does not provide patient benefit.


References/Resources

- Hanley, D. A., Cranney, A., Jones, G., Whiting, S. J., Leslie, W. D. 2010. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary), CMAJ, 182 (12), 1315-1319.
- Hanley, D. A., Cranney, A., Jones, G., Whiting, S. J., Leslie, W. D., Cole, D. E. C., Atkinson, S. A., Josse, R. G., Feldman, S., Kline, G. A., Rosen, C. 2010. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada, CMAJ, 182 (12), E610-E618.
- Souberbielle, J-C., Courbebaisse, M., Cormier, C., Pierrot-Deseilligny, C., Viard, J-P., Jean, G.,
 Cavalier, E. 2012. When should we measure Vitamin D concentration in clinical practice?
 Scandinavian Journal Clinical & Laboratory Investigation. 75 (243), 129-135.
- Institute of Medicine 2010 Report www.nap.edu/read/13050/chapter/1
- Health Canada <u>www.hc-sc.gc.ca/fn-an/nutrition/vitamin/vita-d-eng.php</u>

Patient Impact:

- To facilitate a smooth rollout of the new requisition and lessen impact to both your practice and patient care, there will be a transition period during which the laboratory will accommodate requests for 25(OH)D, that are not received on the new requisition, while continuing to prioritize medically indicated tests:
 - **Phase I February 1-May 1:** All 25(OH)D tests will be processed on the new and old requisitions, as per current practice; ordering practitioners will be alerted to the error if an old requisition was used.

- 1 -







Clinical Practice Change





- Phase II May 2-July 3: Incorrect or incomplete requisitions will result in the sample being collected but held for processing until the correct/completed requisition is received by the DSM laboratory; the sample will be held for one month and then discarded; patients who do not meet the new medical indications will not be eligible for 25(OH)D testing; ordering practitioners will be alerted to the error.
- Phase III Full Implementation Effective July 4: Patient samples will not be drawn when presenting with the incorrect or incomplete requisition; ordering practitioners will be alerted to the error.
- Effective July 4, 2016 DSM labs will not collect blood from patients producing the incorrect or incomplete requisition; follow up to the physician will be done by either the patient or the lab.
- Effective July 4, 2016 samples collected in non-DSM facilities and arriving to the DSM lab with the wrong or incomplete requisition will not be processed; the DSM lab will follow up with the physician and physicians will be responsible for follow up with their patients.
- Medically indicated 25(OH)D tests will continue to be prioritized.

System Improvements:

A reduction in unnecessary 25(OH)D testing will improve service delivery for medically indicated/priority tests.

Background Information

This Clinical Practice Change is an initiative of Choosing Wisely Manitoba. This initiative aims to reduce unnecessary Vitamin D testing by as much as 50%.

Clinical Practice Change issued by: Choosing Wisely Manitoba - Dr. Michael Moffatt, Senior Advisor with the Centre for Healthcare Innovation; Dr. Laurel Thorlacius, Medical Director, Clinical Biochemistry and Genetics, Diagnostic Services Manitoba; Dr. Celia Rodd, Pediatric Endocrinologist; Albert Mota, Project Manager, Centre for Healthcare Innovation

Distribution: This Clinical Practice Change is directed to all ordering professionals in Manitoba

Contact Information:

Questions? Please contact the DSM phone center 204-787-1534, and they will address your concerns or redirect them as required.

More information:

- All 25(OH)D testing for the province is performed at the Diagnostic Services Manitoba Laboratory at the Health Sciences Centre
- Manitoba's new 25(OH)D ordering guidelines are aligned with those of other provinces who have implemented evidence based criteria to increase the appropriate use of this test; Ontario restricted testing in 2010 and in Alberta, as part of the Choosing Wisely initiative, testing was restricted in 2015.
- Patient information tear-off sheets are available by request, please see Appendix B

Choosing Wisely Manitoba and its initiatives to improve patient care are supported by the Manitoba College of Family Physicians, the College of Physicians and Surgeons of Manitoba and Doctors Manitoba.





Clinical Practice Change

Choosing Wisely Manitoba



Appendix A

DIAGNOSTIC SERVICES SERVICES DIAGNOSTICS MANITOBA Vitamin D (25-Hydroxy) Requisition				MS5 Thorlakson Building 820 Sherbrook Street Winnipeg, MB R3A 1R9 Phone: (204) 787-1534 Fax: (204) 787-3473	
s per DSM \$	Specimen Acceptance Policy 10-5		r Test Requisitions 2.1 - All inform e to comply may result in specime	aation marked with an asterisk [*] is mandatory ar en rejection.	nd must be
	ORDERING PROVIDER INF	ORMATION		PATIENT INFORMATION	
ast &Full		Billing Code:	*Last/First Name:		
st Name: rdering		Inpatient	(As per Manitoba Health Card)	
cility:		Location:	*Date of Birth (dd/mm/yyyy):		
dress:			*Sex: Female □Male		
none No:	* Fax No).	***************************************		
DITIONAL	L REPORT RECIPIENT PROVI	IDER INFORMATION	*PHIN:		
ast &Full	L REPORT RECIFIENT PROVI	Billing	*Alternate ID: (include ID)		
st Name:		Code:	with number ie: RCMP, SK, D MRN:		
acility ame:			Encounter Number:		
dress:			Patient Phone No:		
one No:	* Fax No	.		with: Provincial Health Card Armband eCh	art/CR
DITIONAL	L REPORT RECIPIENT PROVI		- #2	COLLECTION INFORMATION	
ast &Full st Name:	E REPORT REGIFIENT FROM	Billing Code:	*Collector:	*Collection D/T: (dd/mm/yyyy)	
acility ame:			Circle for copy of report to referal lab	'ES *Collection Facility:	
dress:			Collected Via: ☐ Venipu	ıncture ☐ Capillary ☐ Indwelling Line ☐ Above S	Shut Off I
one No:	* Fax No).	Referring Lab: Number Serum (no gel)	of tubes sent: Circle if Samples ship	pped froz
	min D (25 Hydroxy) lly necessary 25-hydroxy vi		,	5-hydroxy vitamin D testing that does n	ot mee
l medical least on	lly necessary 25-hydroxy vi	itamin D testing wi	ill be supported by DSM. 2	5-hydroxy vitamin D testing that does n ssary, and will not be performed.	ot mee
l medical least on	lly necessary 25-hydroxy vi e of the testing criteria listo riteria that apply to this pa	itamin D testing wi ed below will be d tient:	ill be supported by DSM. 2	ssary, and will not be performed.	ot mee
l medical least one neck all cr	lly necessary 25-hydroxy vi e of the testing criteria listo riteria that apply to this pa Metabolic bone disease (itamin D testing wi ed below will be d tient: (recurrent fracture	ill be supported by DSM. 29 eemed not medically neces s, rickets, osteomalacia, ost	ssary, and will not be performed.	ot mee
I medical least on neck all cr	lly necessary 25-hydroxy vi e of the testing criteria listo riteria that apply to this pa Metabolic bone disease (Abnormal blood calcium Parathyroid disease	itamin D testing wi ed below will be d tient: (recurrent fracture n, magnesium or ph	ill be supported by DSM. 2! eemed not medically neces s, rickets, osteomalacia, ost	esary, and will not be performed.	
I medical least one neck all cr	lly necessary 25-hydroxy vi e of the testing criteria listo riteria that apply to this pa Metabolic bone disease (Abnormal blood calcium Parathyroid disease	itamin D testing wi ed below will be di tient: (recurrent fracture n, magnesium or ph es (celiac disease, s	ill be supported by DSM. 2! eemed not medically neces s, rickets, osteomalacia, ost nosphate concentrations mall intestine surgery, Cyst	ssary, and will not be performed.	
I medical least on neck all cr	lly necessary 25-hydroxy vi e of the testing criteria listo riteria that apply to this pa Metabolic bone disease (Abnormal blood calcium Parathyroid disease Malabsorption syndrome with vitamin D absorptio	itamin D testing wi ed below will be di tient: (recurrent fracture n, magnesium or ph es (celiac disease, s	ill be supported by DSM. 2! eemed not medically neces s, rickets, osteomalacia, ost nosphate concentrations mall intestine surgery, Cyst	esary, and will not be performed.	
I medical least one neck all co	lly necessary 25-hydroxy vi e of the testing criteria listo riteria that apply to this pa Metabolic bone disease (Abnormal blood calcium Parathyroid disease Malabsorption syndrome with vitamin D absorptio Anticonvulsant agents	itamin D testing wi ed below will be di tient: (recurrent fracture n, magnesium or ph es (celiac disease, s	ill be supported by DSM. 2! eemed not medically neces s, rickets, osteomalacia, ost nosphate concentrations mall intestine surgery, Cyst	esary, and will not be performed.	
I medical least one neck all co	Illy necessary 25-hydroxy vi e of the testing criteria listoriteria that apply to this pa Metabolic bone disease (Abnormal blood calcium Parathyroid disease Malabsorption syndrome with vitamin D absorptio Anticonvulsant agents Chronic renal disease	itamin D testing wi ed below will be di tient: (recurrent fracture n, magnesium or ph es (celiac disease, s	ill be supported by DSM. 2! eemed not medically neces s, rickets, osteomalacia, ost nosphate concentrations mall intestine surgery, Cyst	esary, and will not be performed.	
I medical least ond neck all co	Illy necessary 25-hydroxy vi e of the testing criteria listo riteria that apply to this pa Metabolic bone disease (Abnormal blood calcium Parathyroid disease Malabsorption syndrome with vitamin D absorptio Anticonvulsant agents Chronic renal disease Chronic liver disease	itamin D testing wi ed below will be di tient: (recurrent fracture n, magnesium or ph es (celiac disease, s n cholestyramine,	ill be supported by DSM. 2! eemed not medically neces s, rickets, osteomalacia, ost nosphate concentrations mall intestine surgery, Cyst	eopenia, osteoporosis) ic Fibrosis, or medications that may inte	
I medical least ond neck all co	Illy necessary 25-hydroxy vi e of the testing criteria listo riteria that apply to this pa Metabolic bone disease (Abnormal blood calcium Parathyroid disease Malabsorption syndrome with vitamin D absorptio Anticonvulsant agents Chronic renal disease Chronic liver disease	itamin D testing wi ed below will be di tient: (recurrent fracture n, magnesium or ph es (celiac disease, s n cholestyramine,	ill be supported by DSM. 2! eemed not medically neces s, rickets, osteomalacia, ost nosphate concentrations mall intestine surgery, Cyst orlistat etc)	eopenia, osteoporosis) ic Fibrosis, or medications that may inte	
I medical least ond neck all co	Illy necessary 25-hydroxy vie of the testing criteria listeriteria that apply to this path of the testing criteria listeriteria that apply to this path of the testing criteria that apply to this path of the testing to the path of the testing that apply to the path of the testing that apply to the testing that apply to the testing that apply t	itamin D testing wi ed below will be di tient: (recurrent fracture n, magnesium or ph es (celiac disease, s n cholestyramine,	ill be supported by DSM. 2! eemed not medically neces s, rickets, osteomalacia, ost nosphate concentrations mall intestine surgery, Cyst orlistat etc)	eopenia, osteoporosis) ic Fibrosis, or medications that may inte	






Clinical Practice Change

Choosing Wisely Manitoba



Appendix B

Patient information tear-off sheets are available by request – 5.5" x 8.5" pads of 100. Please contact Krista Hand – $\frac{khand@dsmanitoba.ca}{khand}$ or 926.8005



- 4 -

This Clinical Practice Change is a directive of Choosing Wisely Manitoba, an initiative to improve the appropriate use of diagnostic testing in our province.

CWM is a partnership of the Centre for Healthcare Innovation and Diagnostic Services Manitoba.



